MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務。

Cilengitide TFA

CAS No. : 199807-35-7

產品活性：Cilengitide is a potent and selective integrin inhibitor for α_vβ₃ and α_vβ₅ receptor, with IC₅₀ values of 4 nM and 79 nM, respectively.

研究領域：Cytoskeleton  |  Autophagy

作用靶點：Integrin  |  Autophagy

In Vitro: Cilengitide (EMD 121974) is the α_vβ₃ and α_vβ₅ integrin receptor antagonist. In cell adhesion studies assessing the human melanoma M21 or UCLA-P3 human lung carcinoma cell lines, Cilengitide inhibits integrin-mediated binding to vitronectin with IC₅₀s of 0.4 and 0.4 μM. In vitro treatment of Cilengitide, at a concentration greater than 1 µM, shows concentration- and time-dependent cytotoxic effects .

In Vivo: In nude mice bearing M21-L melanoma tumors, Cilengitide dose i.p. at 10, 50, and 250 μg three times per week demonstrate inhibition of tumor growth with a reduction in both tumor volume (55%, 75%, and 89%, respectively) and tumor weight (23%, 38%, and 61%, respectively), when compared to controls. In the rat model studied, the systemic pharmacokinetics of i.p. Cilengitide are not affected by ILP with Cilengitide alone or ILP with Cilengitide plus Melphalan, TNF or both. Systemic Cilengitide levels reach around 20 µg/mL (approximately 35 µM) within 10 min of i.p. administration and continued to rise to approximately 40 µg/mL (approximately 70 µM) in the first hour. Thereafter Cilengitide levels in serum drop with an elimination half-life of 2.1 hr.

相關產品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Autophagy Compound Library  |  Drug Repurposing Compound Library  |  Macrocyclic Compound Library  |  Cytoskeleton Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Rare Diseases Drug Library  |  Anti-Prostate Cancer Compound Library  |  Membrane Protein-targeted Compound Library  |  GRGDSPK  |  EILEVPST  |  Arg-Gly-Asp-Ser TFA  |  MK-0429  |  Tirofiban hydrochloride monohydrate  |  Anti-Mouse IL-1a Antibody  |  Echistatin  |  TC113  |  BIRT 377  |  αvβ1 integrin-IN-1  |  Enlimomab  |  Lys-Gln-Ala-Gly-Asp-Val  |  TC-I 15  |  Valategrast hydrochloride  |  Carotegrast  |  Irigenin  |  Integrin modulator 1  |  αvβ5 integrin-IN-1  |  RGD  |  Abituzumab  |  Zaurategrast  |  Surfactin C1  |  BOP sodium  |  Tirofiban-d₉  |  α2β1 Integrin Ligand Peptide TFA  |  Fradafiban  |  Firategrast  |  SB-273005  |  Fibronectin

熱門產品線：重組蛋白  |  化合物庫  |  天然產物  |  熒光染料  |  PROTAC  |  同位素標記物  |  寡核苷酸  |  抗體  |  點擊化學

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫，我們致力于為全球科研客戶提供前沿的高品質小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領；
•   產品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產品，廣泛應用于新藥研發、生命科學等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學分析檢測分析，藥物篩選等專業技術服務；
•   設有專業的實驗中心和嚴格的質控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告，確保產品的高純度、高品質；
•   產品的生物活性多經各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業團隊跟蹤最新的制藥及生命科學研究進展，為您提供全球新的活性化合物；
•   與世界各大制藥公司及著名科研機構建立了長期的合作。